Clinical Research and Regulatory Affairs: Global Industry Report

Summary

Clinical research and regulatory affairs sit between drug developers, trial sites and regulators. One market researcher estimates the global regulatory affairs market at USD 17.68 billion, with clinical studies holding the largest share at 48.87 percent ⁶. Another firm lists regulatory affairs outsourcing at USD 7.7 billion, with pharmaceutical companies as the largest end-use group ⁵. The estimates use different scopes and are not reconciled. The clearest operating pressure is at the trial site. In United States survey data, 59 percent of sites report fewer eligible patients recruited because of process inefficiencies ⁷, and more than 40 percent report staffing shortages ⁸. Regulation is converging: ICH E6(R3) has stated legal effective dates in the European Union, is incorporated by reference into Australian law, and carries transition arrangements in Switzerland ¹²⁴. The outlook favors simpler trial designs and better site support, but the pack lacks reliable evidence on costs, equity, digital adoption and public versus private site performance.

Key findings

1. 1

   Clinical studies is the largest segment in two market estimates

   One vendor estimate puts clinical studies at 48.87 percent of the regulatory affairs market, linked to growing trial numbers and compliance demands. Estimates are vendor-produced and not verified against official statistics.

   Confidence: Medium
2. 2

   Recruitment inefficiency is widely reported by US sites

   About 59 percent of US clinical trial sites report fewer eligible patients recruited due to recruitment process inefficiencies. The figure comes from a survey reported in a news article and is not a verified national rate.

   Confidence: Medium
3. 3

   Staffing shortages affect most US sites and coordinator roles

   More than 40 percent of clinical research sites report a staffing shortage across all site roles, and two-thirds report a shortage of clinical research coordinators. More than half expect shortages to worsen. The source is a sponsor-affiliated vendor survey.

   Confidence: Medium
4. 4

   ICH E6(R3) status differs by jurisdiction

   The EU presents Principles and Annex 1 with a stated legal effective date. Australia incorporates the GCP guideline into law by reference and allows either E6(R2) or E6(R3) during a transition. Switzerland expects investigators holding an E6(R2) certificate to self-study the revised guideline.

   Confidence: High
5. 5

   Market size estimates diverge and cannot be combined

   One source lists regulatory affairs outsourcing at USD 7.7 billion while another lists the total regulatory affairs market at USD 17.68 billion. Differences in scope and method mean the figures should not be treated as one series.

   Confidence: Qualitative
6. 6

   Worldwide staffing concern is reported qualitatively

   A survey of Association for Clinical Research Professionals members, as reported by CRIO and TPS, found staffing shortages at research sites having a major impact on trials worldwide. No global headcount is available in the pack.

   Confidence: Qualitative

1Industry definition and scope

This report covers clinical research and regulatory affairs: the work that designs, runs and documents clinical studies, and the regulatory activity that supports medicine development and approval. The scope is global, anchored on ICH guidance and regulator publications from the European Union, Switzerland and Australia. United States survey data is used for trial site operations because it is the strongest site-level evidence in the pack.

Four stakeholder groups are in scope. Sponsors, mainly pharmaceutical companies, commission studies and submissions ⁵. Outsourcing and research service providers carry out part of this work. Trial sites recruit and manage participants. Regulators set and enforce standards ³. Trial participants are included because the guidance is written to limit unnecessary burden on them ³.

Terms are used as the sources use them. Market researchers use regulatory affairs broadly, and segment labels such as clinical studies are not defined in the pack. This matters because market totals differ (see Section 2). The reporting period is the latest available data in the pack, and forecasts are labeled as vendor projections. Clinical care delivery is outside scope except where trial sites are involved.

Scope follows the sources in the pack. No independent definition of the industry boundary was available.

2Market size, structure and value chain

Market size estimates in the pack come from market research firms, not official statistics. One firm lists the global regulatory affairs market at USD 17.68 billion as an estimate and forecasts growth to about USD 40.13 billion ⁶. The forecast horizon is not confirmed in the pack, so no growth rate is given here. A second firm lists regulatory affairs outsourcing at USD 7.7 billion ⁵. The two totals cover different scopes and should not be added or compared as one series.

Both research firms show clinical studies as the largest segment. The clinical studies segment held 45 percent of outsourcing revenue ⁵ and a 48.87 percent share of the broader regulatory affairs market ⁶. The source links that share to growing trial numbers and compliance demands. Pharmaceutical companies held the largest end-use share at 38 percent of outsourcing revenue ⁵. These shares apply to different totals and are each firm's own observed figures.

Value chain (writer's interpretation): sponsors commission design, regulatory submissions and monitoring, often through outsourcing providers. Sites recruit and treat participants under the protocol. Regulators review data and oversee conduct. The pack gives no data on pricing, contract structure, revenue models or margins for any link. This is a data gap.

Reconciling the USD 7.7 billion and USD 17.68 billion figures requires the underlying methods, which are not in the pack. The spread reflects differences in definition and vendor method rather than a measured change in the market.

• Clinical studies share of the regulatory affairs market 48.87percent of market share Observed Global, Latest available data [6]
• Regulatory affairs outsourcing market size 7.7USD billion Observed Global, Latest available data [5]

Shares are reported as stated by each vendor. The 17.68 billion figure is an estimate and the forecast of 40.13 billion is a vendor projection.

3Customers, demand and adoption

Sponsors need trials to enroll on time, and sites report that recruitment is hard. About 59 percent of United States clinical trial sites report fewer eligible patients recruited due to recruitment process inefficiencies ⁷. In a survey of 100 United States site employees, 52 percent said at least 20 percent of referrals were ineligible before screening began ⁷. These are survey results reported in a news article and reflect site experience, not verified trial-wide rates.

A cited survey in a news article reports that 29 percent of sites that take on a trial fail to enroll patients ¹⁰. The geography and period are not specified in the source, so this figure should not be combined with the United States results.

Demand drivers include growing trial numbers and compliance demands ⁶. Regulatory expectations are also changing. ICH E6(R3) encourages operationally feasible trial processes that avoid unnecessary complexity and states that sponsors should not place unnecessary burden on participants and investigators ³. This is established guidance, and its practical effect on recruitment is not measured in the pack.

Buyer purchasing criteria, patient or participant equity and diversity indicators, and adoption rates of digital trial tools are not verified in the pack. These are data gaps. Nothing in this section is individual medical advice.

• Sites reporting fewer eligible patients recruited due to process inefficiencies 59percent of sites Observed United States, Latest available data [7]

The site survey is sponsor-affiliated according to the source limitations list and is not a representative national sample.

4Competitive landscape and key players

Named companies in the pack are few, and most are data providers or survey sponsors rather than trial service providers with disclosed financials. Grand View Research ⁵ and Cervicorn Consulting ⁶ segment the market but do not provide company market shares in the pack, so concentration cannot be measured. Comparable examples are limited.

Advarra, described in the pack as a vendor, publishes a workforce survey on clinical research sites ⁸. CRIO and TPS, also vendors, report on staffing shortages and on sponsor support to sites ⁹. Because both groups sell workforce or site-support solutions, their findings should be read with that commercial interest in mind, even where the survey data is useful.

myTomorrows, reported through Fierce Biotech, surveyed sites on recruitment inefficiency ⁷. The source limitations list describes this and the Advarra survey as sponsor-affiliated, so results reflect the views of parties with a stake in recruitment tools.

The pack contains no comparison of public, private or community research sites on cost, quality or timeliness, so provider types cannot be compared fairly. The competitive pressure described is labor and recruitment capacity rather than price (writer's interpretation). Vendor claims about differentiation are not tested here.

Company examples come from survey and research publishers. No financial or operating data for trial service providers was verified.

5Technology, operations and workforce

Workforce is the best-documented constraint in the pack, though the strongest figures are United States only. More than 40 percent of clinical research sites report a staffing shortage across all site roles ⁸. Two-thirds report a shortage of clinical research coordinators, and more than half expect shortages to worsen ⁸.

A survey of Association for Clinical Research Professionals members, as reported by CRIO and TPS, found staffing shortages at research sites having a major impact on trials worldwide ⁹. This is a qualitative worldwide finding. No global count of clinical research workers or coordinators is available in the pack.

Talent supply is also under pressure. A cited survey found physician entry into clinical research dropped from 5 percent to less than 2 percent annually ¹⁰. The article does not give geography or period, so the trend should be treated with caution.

Established practice in this area is guideline-led process design ³. The pack does not verify adoption rates of digital health, electronic data capture, automation or AI in clinical research, so emerging tools cannot be assessed against evidence here. Productivity measures are not available.

• Sites reporting a staffing shortage across all site roles more than 40percent of sites Observed United States, Latest available data [8]

Workforce figures come from vendor-sponsored surveys and are not representative of all sites.

6Regulation, standards, risk and sustainability

European Union: EMA lists ICH E6(R3) Principles and Annex 1 as the current version, with a stated legal effective date of 23 July, and Annex 2 with a legal effective date of 15 January ¹. EMA presents these as legal effective dates. Readers should confirm the legal text with the EMA before relying on it.

Australia: the TGA adopted E6(R3) Principles and Annex 1 with a transition period allowing either E6(R2) or E6(R3) compliance ². The ICH GCP guideline is incorporated into Australian law by reference in the Therapeutic Goods Regulations ², which makes it binding in that jurisdiction.

Switzerland: Swissmedic reports that E6(R3) Principles and Annex 1 entered into force on 15 August ⁴. Swissmedic and swissethics expect principal investigators holding an E6(R2) certificate to self-study the revised guideline ⁴. This is a regulator expectation, and the source does not describe penalties.

Standards and risk: ICH E6(R3) is the international guideline ³. Privacy, data protection, environmental and social factors are not covered by sources in the pack, and these are gaps. Operational risk is evidenced mainly by the site inefficiency and staffing data above. This is regulatory context, not legal advice.

Binding status is stated only where the source describes legal incorporation or legal effective dates. Expectations and voluntary guidance are labeled as such.

7Challenges, opportunities and case examples

Constraints: recruitment inefficiency ⁷, ineligible referrals ⁷, staffing shortages ⁸⁹ and a thinning physician pipeline ¹⁰ combine to slow trials. The pack does not quantify the cost or delay caused by these constraints.

Opportunities: E6(R3) encourages simpler, feasible processes ³, giving sponsors a regulatory basis to reduce complexity. CRIO and TPS argue that sponsors can provide support to sites ⁹. The pack does not test whether this approach improves enrollment.

Case examples: (1) Swissmedic and swissethics set out a self-study expectation for investigators moving from E6(R2) to E6(R3) ⁴. (2) The TGA's transition arrangement lets sponsors and sites choose between E6(R2) and E6(R3) for a period ². (3) The Advarra workforce survey ⁸ and the myTomorrows recruitment survey ⁷ show how site-level evidence is currently generated by vendor or sponsor-linked research.

Limits: no case reports a before and after measure of enrollment, cost or time to approval. Comparable company-level outcome data is not in the pack.

Case examples are drawn from regulator and survey sources in the pack. Company outcomes were not available.

8Outlook and strategic implications

Near term: staffing and recruitment constraints are likely to persist, since more than half of sites expect shortages to worsen ⁸. This is a survey expectation, not a verified forecast.

Medium term: market estimates point to growth. One firm forecasts the regulatory affairs market to rise to about USD 40.13 billion ⁶. The forecast is vendor-produced and its method is not verified, so treat it as a directional view only.

Implications (writer's interpretation): sponsors may reduce protocol complexity and invest in site support, since E6(R3) encourages feasible design ³. Sites need recruitment and staffing capacity to convert referrals into enrolled participants ⁷⁸. Because the EU, Australia and Switzerland run different transition arrangements ¹²⁴, compliance planning should be multi-jurisdictional. Vendors should publish methods so that survey and forecast claims can be tested.

Outlook statements combine regulator dates, survey expectations and vendor forecasts, each labeled by source type.

9Conclusion

The most defensible view is that clinical research and regulatory affairs are shaped by recruitment inefficiency and workforce shortage at trial sites, while ICH E6(R3) sets a shared standard that is being adopted on different timelines across the EU, Australia and Switzerland ¹²⁴⁷⁸. Market size estimates diverge and should be treated as directional.

How this was built

Sources

1. 1

   ICH E6 Good clinical practice - Scientific guideline

   European Medicines Agency Regulator

   ema.europa.eu
2. 2

   ICH Guideline for Good Clinical Practice

   Therapeutic Goods Administration (Australia) Regulator

   tga.gov.au
3. 3

   ICH E6(R3) Guideline for Good Clinical Practice (Step 4 final version)

   International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Standard

   database.ich.org
4. 4

   Swissmedic: Adoption of ICH GCP Guideline E6(R3)

   Swissmedic Regulator

   swissmedic.ch
5. 5

   Regulatory Affairs Outsourcing Market Size Report

   Grand View Research Market research

   grandviewresearch.com
6. 6

   Regulatory Affairs Market Size, Share, Report

   Cervicorn Consulting Market research

   cervicornconsulting.com
7. 7

   Over half of clinical trial sites see recruitment hindered by inefficiencies: survey

   Fierce Biotech (reporting a myTomorrows survey) News report

   fiercebiotech.com
8. 8

   Survey Report: The State of Workforce Development

   Advarra Vendor report

   resource.advarra.com
9. 9

   Staffing Shortages in Clinical Research Highlight Opportunities for Sponsors to Provide Support

   CRIO and TPS (with ACRP member survey) Vendor report

   clinicalresearch.io
10. 10

    Clinical Trials Have a Research Site Demand and Supply Crisis. Here is How to Solve it

    MedCity News News report

    medcitynews.com